Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × AMG 757 × NET × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1 Neoplasms 1

Interventions

lutetium Lu 177 dotatate 18 Temozolomide 12 Everolimus 12 Nivolumab 8 Capecitabine 8 cabozantinib 7 pembrolizumab 6 Sunitinib 6 Magnetic Resonance Spectroscopy 5 lanreotide 4 gallium Ga 68 dotatate 4 Specimen Handling 4 Etoposide 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 telotristat ethyl 3 pazopanib 3 lenvatinib 3 avelumab 3 Octreotide 3 Ipilimumab 3 Injections 3 Fluorodeoxyglucose F18 3 Cyclophosphamide 3 Cisplatin 3 Carboplatin 3 Bevacizumab 3 surufatinib 2 sintilimab 2 fosbretabulin 2 fludarabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06502977 2025-10-28

DeLLphi-307

Amgen

Phase 2 Active not recruiting

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡